e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Diffuse parenchymal lung disease III
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early single centre Irish experience
P. Barry, L. Murphy, M. Tuohy, E. Judge, J. Egan (Dublin, Ireland)
Source:
Annual Congress 2012 - Diffuse parenchymal lung disease III
Session:
Diffuse parenchymal lung disease III
Session type:
Thematic Poster Session
Number:
3663
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Barry, L. Murphy, M. Tuohy, E. Judge, J. Egan (Dublin, Ireland). Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early single centre Irish experience. Eur Respir J 2012; 40: Suppl. 56, 3663
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Related content which might interest you:
Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP)
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Idiopathic pulmonary fibrosis (IPF): the patient journey
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 695-696
Year: 2010
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 35: 821-829
Year: 2010
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept